HC Wainwright & Co. reiterated coverage on Cara Therapeutics with a new price target

8/24/21 6:11:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of Cara Therapeutics with a rating of Buy and set a new price target of $35.00 from $33.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CARA

Date	Price Target	Rating	Analyst
6/13/2024	$6.00 → $1.00	Buy → Hold	Stifel
6/13/2024	$10.00 → $1.00	Buy → Hold	Canaccord Genuity
6/13/2024		Buy → Hold	Needham
6/13/2024		Buy → Neutral	H.C. Wainwright
3/8/2023	$13.00 → $6.00	Neutral → Underperform	BofA Securities
3/8/2022	$17.00 → $20.00	Neutral → Overweight	JP Morgan
11/1/2021	$33.00	Buy	Canaccord Genuity
8/24/2021	$33.00 → $35.00	Buy	HC Wainwright & Co.